A very small proportion of children with rare autoimmune and rheumatological disorders, such as juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, juvenile dermatomyositis and other systemic vasculitides will respond neither to the classical anti-inflammatory and/or immunosuppressive treatments, nor to the new and emerging biologic response modifiers. This small group of children,...
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.